|
About KPMG
Events
Pharmaceutical Industry under the Microscope
| Date: |
Thu, 17 December 2009 |
| Time: |
1:30 p.m. - 2:00 p.m.
(Registration)
2:00 p.m. - 5:00 p.m.
(Presentation)
|
| Venue: |
JW Marriott, Tomorrow Square
399 Nanjing West Road, Shanghai |
| Language: |
English |
| Fee: |
There is no fee for attending. Seating is limited so early registration is recommended. |
| Other speaker: |
Marc Rivers
Finance Director
Shanghai Roche Pharmaceuticals Ltd. |
| KPMG speakers: |
Steven Tseng 
Partner in charge, China & Asia Pacific Leader
Global Transfer Pricing Services
KPMG China |
| |
Cheng Chi
Partner, Global Transfer Pricing Services
KPMG China, Shanghai |
| |
Nathan Richards
Director, Global Transfer Pricing Services
KPMG in China, Hong Kong |
| |
Constance Lin
Senior Manager, Global Transfer Pricing Services
KPMG in China, Shanghai |
China's State Administration of Taxation (SAT) has recently instructed tax authorities across China to "focus" on the pharmaceutical industry and some other sectors, leading to transfer pricing and tax investigations in multiple cities and areas. In supporting this campaign, the SAT devoted its annual transfer pricing training around the pharmaceutical industry: what does this new development mean for pharmaceutical companies operating in China?
KPMG's Global Transfer Pricing Services team of over 450 full-time transfer pricing specialists in the Asia-Pacific region is organized by industry lines, and already has a specialist team focusing on the pharmaceutical clients. During the seminar, this team will draw on their expertise to equip participants with the tools and knowledge necessary to be prepared to respond to inquiries from the tax authorities, should they occur, as well as to better and more proactively manage their transfer pricing risks in the current climate.
We believe given the recent increase in scrutiny from the SAT towards the pharmaceutical industry in particular, it is vital that these companies give due consideration to their tax profile. Specifically, companies should be evaluating their transfer pricing exposures, assessing their potential transfer pricing risks related to restructuring, and considering the tax implications of local marketing, advertising, and promotional activities.
|
|
|
CONTACT US
